2022 World Conference on Lung Cancer (ePosters)-EP11.01-003. Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation

Pdf Summary

A study was conducted to investigate the prevalence of EGFR Exon 20 Insertion mutations in patients with advanced non-small cell lung cancer (NSCLC) and its potential implications for clinical practice. The study included a total of 497 cases of advanced NSCLC, and genetic mutations were identified using the NGS technique.<br /><br />The results showed that EGFR Exon 20 Insertion mutations accounted for approximately 10% of all EGFR mutations in advanced NSCLC. There were 203 cases with EGFR mutations, out of which 21 cases (10.34%) had single EGFR Exon 20 Insertion mutations, and 6 cases (2.96%) had compound EGFR Exon 20 Insertion mutations. The total number of cases with EGFR Exon 20 Insertion mutations was 28 (13.79% of all EGFR mutations).<br /><br />Further analysis revealed that 13 out of the 28 cases (46.43%) of EGFR Exon 20 Insertion mutations had a subtype known as C-helix, which was sensitive to first, second, and third-generation EGFR tyrosine kinase inhibitors (TKIs). The remaining 15 cases (53.57%) had subtypes other than C-helix, which were sensitive to new generation TKIs such as Amivantamab and Mobocertinib.<br /><br />The study highlighted the importance of using NGS to identify the various subtypes of EGFR Exon 20 Insertion mutations. It also noted that there are targeted therapies available for all subtypes of this mutation, emphasizing the need for personalized treatment approaches based on the specific subtype of the mutation.<br /><br />In conclusion, EGFR Exon 20 Insertion mutations are a rare type of EGFR mutation that is resistant to first, second, and third-generation TKIs. However, newer targeted therapies have shown promise in treating these mutations. The study findings provide valuable insights into the prevalence and subtypes of EGFR Exon 20 Insertion mutations in advanced NSCLC, helping to inform clinical practice and improve treatment outcomes for patients.

Asset Subtitle

Nguyen Son Lam

Meta Tag

Speaker Nguyen Son Lam

Topic Pathology - Genomics & Analytics

Keywords

EGFR Exon 20 Insertion mutations

advanced non-small cell lung cancer

prevalence

clinical practice

NGS technique

genetic mutations

C-helix subtype

first-generation EGFR tyrosine kinase inhibitors

second-generation EGFR tyrosine kinase inhibitors

third-generation EGFR tyrosine kinase inhibitors